These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 11190351)

  • 1. Antipseudomonal antibiotics.
    Giamarellou H; Antoniadou A
    Med Clin North Am; 2001 Jan; 85(1):19-42, v. PubMed ID: 11190351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current therapies for pseudomonas aeruginosa.
    Giamarellou H; Kanellakopoulou K
    Crit Care Clin; 2008 Apr; 24(2):261-78, viii. PubMed ID: 18361945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
    Lee CH; Su TY; Ye JJ; Hsu PC; Kuo AJ; Chia JH; Lee MH
    J Microbiol Immunol Infect; 2017 Oct; 50(5):677-683. PubMed ID: 26188977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Change in antipseudomonal carbapenem susceptibility in 25 hospitals across 9 years is not associated with the use of ertapenem.
    Eagye KJ; Nicolau DP
    J Antimicrob Chemother; 2011 Jun; 66(6):1392-5. PubMed ID: 21459897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combinations of antibiotics against Pseudomonas aeruginosa.
    Baltch AL; Smith RP
    Am J Med; 1985 Jul; 79(1A):8-16. PubMed ID: 3927722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pseudomonas aeruginosa susceptibility in a university hospital: recognition and treatment.
    Rotschafer JC; Shikuma LR
    Drug Intell Clin Pharm; 1986; 20(7-8):575-81. PubMed ID: 3091346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibiotic susceptibility patterns of Pseudomonas aeruginosa to available antipseudomonal drugs in Ibadan, Nigeria.
    Ogbolu DO; Ogunledun A; Adebiyi OE; Daini OA; Alli AO
    Afr J Med Med Sci; 2008 Dec; 37(4):339-44. PubMed ID: 19301711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pseudomonas aeruginosa: arsenal of resistance mechanisms, decades of changing resistance profiles, and future antimicrobial therapies.
    El Zowalaty ME; Al Thani AA; Webster TJ; El Zowalaty AE; Schweizer HP; Nasrallah GK; Marei HE; Ashour HM
    Future Microbiol; 2015; 10(10):1683-706. PubMed ID: 26439366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergence of highly antibiotic-resistant Pseudomonas aeruginosa in relation to duration of empirical antipseudomonal antibiotic treatment.
    Philippe E; Weiss M; Shultz JM; Yeomans F; Ehrenkranz NJ
    Clin Perform Qual Health Care; 1999; 7(2):83-7. PubMed ID: 10747571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?
    Banerjee D; Stableforth D
    Drugs; 2000 Nov; 60(5):1053-64. PubMed ID: 11129122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Multiply resistant Pseudomonas aeruginosa in the pediatric field].
    Tabuki K
    Nihon Rinsho; 1991 Oct; 49(10):2387-92. PubMed ID: 1660948
    [No Abstract]   [Full Text] [Related]  

  • 12. Occurrence of antipseudomonal beta-lactams and aminoglycosides resistance in Pseudomonas aeruginosa during therapy.
    Pagani L; Scarabelli M; Cereda PM; Debiaggi M
    Microbiologica; 1987 Jan; 10(1):103-10. PubMed ID: 3106759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Some newer antimicrobial agents with antipseudomonal activity.
    Pritchard RC
    Med J Aust; 1989 Jun; 150(12):708-11, 714-5. PubMed ID: 2543891
    [No Abstract]   [Full Text] [Related]  

  • 14. Multicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocomial infections.
    Van Eldere J
    J Antimicrob Chemother; 2003 Feb; 51(2):347-52. PubMed ID: 12562701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposomal antibiotic formulations for targeting the lungs in the treatment of Pseudomonas aeruginosa.
    Alipour M; Suntres ZE
    Ther Deliv; 2014 Apr; 5(4):409-27. PubMed ID: 24856168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipseudomonal penicillins.
    Tan JS; File TM
    Med Clin North Am; 1995 Jul; 79(4):679-93. PubMed ID: 7791416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy.
    Riou M; Carbonnelle S; Avrain L; Mesaros N; Pirnay JP; Bilocq F; De Vos D; Simon A; Piérard D; Jacobs F; Dediste A; Tulkens PM; Van Bambeke F; Glupczynski Y
    Int J Antimicrob Agents; 2010 Dec; 36(6):513-22. PubMed ID: 20926262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceftolozane-tazobactam resistance induced in vivo during the treatment of MDR Pseudomonas aeruginosa pneumonia.
    Plant AJ; Dunn A; Porter RJ
    Expert Rev Anti Infect Ther; 2018 May; 16(5):367-368. PubMed ID: 29727213
    [No Abstract]   [Full Text] [Related]  

  • 19. Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions.
    Giamarellou H
    Am J Med; 1986 Jun; 80(6B):126-37. PubMed ID: 3088998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of antipseudomonal antimicrobic agents.
    Gilbert DN
    Antibiot Chemother (1971); 1985; 36():111-33. PubMed ID: 3923909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.